At the news
? MIXEDIMPACT 5/10 6-K filed Jul 27, 2026 at 07:07 ET
AstraZeneca reported Phase III results for Ultomiris in HSCT-TMA: the adult/adolescent trial (ALXN1210-TMA-313) failed to meet its primary endpoint of event-free survival, while the pediatric trial (ALXN1210-TMA-314) showed previously disclosed clinically meaningful overall survival (87.2% at 26 weeks). The company is advancing regulatory filings for the pediatric indication, but the adult indication faces an uncertain path pending ongoing health authority discussions.
- Ultomiris did not achieve statistical significance for the primary endpoint (event-free survival through 26 weeks) in the Phase III ALXN1210-TMA-313 trial in adults and adolescents with HSCT-TMA.
- In the pediatric Phase III ALXN1210-TMA-314 trial, Ultomiris demonstrated clinically meaningful overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks (previously disclosed).
- Alexion, AstraZeneca Rare Disease, is advancing regulatory filings for Ultomiris in pediatric HSCT-TMA based on these results and an external control study.
- Ultomiris has Orphan Drug Designation in the US and Japan for HSCT-TMA and Breakthrough Therapy designation from the FDA for pediatric patients with HSCT-TMA.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access